Replies to post #178683 on Biotech Values

[DewDiligence]

MNTA receives orphan status for [M402] pancreatic cancer treatment.

Is it a coincidence that GS resumed coverage of MNTA earlier today (before the OD news) with a $19 target (#msg-102759056)?

[DewDiligence]

MNTA—Necuparanib (M402) PR on phase-1 portion of phase-1/2 trial in pancreatic cancer:

http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=875538

Reminder: MNTA is holding an R&D Day webcast tomorrow from 8:30am-Noon ET.